Interactive Audience Q&A: What’s Next for Biomarkers & Clinical Trial Design in Myasthenia Gravis & Autoimmune Neuropathies?
- Exploring the biggest unresolved challenges in biomarkers, patient stratification and clinical trial design across MG, CIDP, GBS and MMN, identifying where the field still lacks consensus and where future research should focus
- Separating established scientific understanding from emerging hypotheses by examining which biomarkers, endpoints and development strategies continue to add value, and which are becoming less informative as the treatment landscape evolves
- Opportunities to strengthen translational research, improve trial design and accelerate precision medicine across heterogeneous patient populations